Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

ClinicalTrials.gov ID: NCT00788944

Public ClinicalTrials.gov record NCT00788944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Outpatients With Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and other chemicals).

Study identification

NCT ID
NCT00788944
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
971 participants

Conditions and interventions

Conditions

Interventions

Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2008
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009
Last update posted
Jan 6, 2011

2008 – 2009

United States locations

U.S. sites
52
U.S. states
28
U.S. cities
49
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35216
Pfizer Investigational Site Tuscon Arizona 85710
Pfizer Investigational Site Little Rock Arkansas 72223
Pfizer Investigational Site National City California 91950
Pfizer Investigational Site Oceanside California 92056
Pfizer Investigational Site Santa Ana California 92701
Pfizer Investigational Site Temecula California 92591
Pfizer Investigational Site Colorado Springs Colorado 80909
Pfizer Investigational Site Denver Colorado 80204
Pfizer Investigational Site Cromwell Connecticut 06416
Pfizer Investigational Site Milford Connecticut 06460
Pfizer Investigational Site Coral Gables Florida 33134
Pfizer Investigational Site Lauderhill Florida 33319
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site West Palm Beach Florida 33409
Pfizer Investigational Site Decatur Georgia 30033
Pfizer Investigational Site Naperville Illinois 60563
Pfizer Investigational Site Wichita Kansas 67207
Pfizer Investigational Site Wichita Kansas 67211
Pfizer Investigational Site Crestview Hills Kentucky 41017
Pfizer Investigational Site Florence Kentucky 41042
Pfizer Investigational Site Columbia Maryland 21045
Pfizer Investigational Site Pittsfield Massachusetts 01201
Pfizer Investigational Site Watertown Massachusetts 02472
Pfizer Investigational Site Kalamazoo Michigan 49009
Pfizer Investigational Site Stevensville Michigan 49127
Pfizer Investigational Site Chesterfield Missouri 63017
Pfizer Investigational Site Jefferson City Missouri 65109
Pfizer Investigational Site Kalispell Montana 59901
Pfizer Investigational Site Las Vegas Nevada 89119
Pfizer Investigational Site Albuquerque New Mexico 87108
Pfizer Investigational Site Brooklyn New York 11223
Pfizer Investigational Site Brooklyn New York 11235
Pfizer Investigational Site Staten Island New York 10312
Pfizer Investigational Site Charlotte North Carolina 28209
Pfizer Investigational Site Wilmington North Carolina 28401
Pfizer Investigational Site Bismarck North Dakota 58051
Pfizer Investigational Site Fargo North Dakota 58104
Pfizer Investigational Site Cincinnati Ohio 45245
Pfizer Investigational Site Kettering Ohio 45429
Pfizer Investigational Site Mason Ohio 45040
Pfizer Investigational Site Norman Oklahoma 73069
Pfizer Investigational Site Oklahoma City Oklahoma 10213
Pfizer Investigational Site Bridgeville Pennsylvania 15017
Pfizer Investigational Site Philadelphia Pennsylvania 19139
Pfizer Investigational Site Pottstown Pennsylvania 19464
Pfizer Investigational Site Reading Pennsylvania 19606
Pfizer Investigational Site Greenville South Carolina 29615
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Bellevue Washington 98004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00788944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2011 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00788944 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →